tbuckley/cabot-search huggingface dataset:
Current State of Cardiovascular Research in Korea
Authors: Jae Il Shin, Jaewon Oh, Hyeon Chang Kim, Donghoon Choi, Young-sup Yoon
Journal: Circulation Research (2019)

Cardiovascular diseases have shown a continuous increase in Korea over the past decade and became the second most common cause of mortality in Korea. Although the number and the amount of total grants for cardiovascular research have increased in Korea, the proportion of the number of grants and total amount allocated for the cardiac/cardiovascular field to all health and medical research fields has not changed much over this period. In addition, the publications related to clinical research have substantially increased in Korea along with the number of nation-wide registries for cardiovascular diseases, but basic and translational research did not show significant growth, requiring new measures to promote basic and translational cardiovascular research in Korea.
Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
Authors: Sierra Cheng, Matthew C. Cheung, Di Maria Jiang, Erica McDonald, Vanessa S. Arciero, Doreen Anuli Ezeife, Amanda Rahmadian, Alexandra Chambers, Kelley-Anne Sabarre, Ambika Parmar, Kelvin K.W. Chan
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Clinical benefit scores (CBS) are key elements of the ASCO Value Framework (ASCO-VF) and are weighted based on a hierarchy of efficacy endpoints: hazard ratio for death (HR OS), median overall survival (mOS), HR for disease progression (HR PFS), median progression-free survival (mPFS), and response rate (RR). When HR OS is unavailable, the other endpoints serve as “surrogates” to calculate CBS. CBS are computed from PFS or RR in 39.6% of randomized controlled trials. This study examined whether surrogate-derived CBS offer unbiased scoring compared with HR OS–derived CBS. Methods: Using the ASCO-VF, CBS for advanced disease settings were computed for randomized controlled trials of oncology drug approvals by the FDA, European Medicines Agency, and Health Canada in January 2006 through December 2017. Mean differences of surrogate-derived CBS minus HR OS–derived CBS assessed the tendency of surrogate-derived CBS to overestimate or underestimate clinical benefit. Spearman’s correlation evaluated the association between surrogate- and HR OS–derived CBS. Mean absolute error assessed the average difference between surrogate-derived CBS relative to HR OS–derived CBS. Results: CBS derived from mOS, HR PFS, mPFS, and RR overestimated HR OS–derived CBS in 58%, 68%, 77%, and 55% of pairs and overall by an average of 5.62 (n=90), 6.86 (n=110), 29.81 (n=101), and 3.58 (n=108), respectively. Correlation coefficients were 0.80 (95% CI, 0.70–0.86), 0.38 (0.20–0.53), 0.20 (0.00–0.38), and 0.01 (–0.18 to 0.19) for mOS-, HR PFS–, mPFS-, and RR-derived CBS, respectively, and mean absolute errors were 11.32, 12.34, 40.40, and 18.63, respectively. Conclusions: Based on the ASCO-VF algorithm, HR PFS–, mPFS-, and RR-derived CBS are suboptimal surrogates, because they were shown to be biased and poorly correlated to HR OS–derived CBS. Despite lower weighting than OS in the ASCO-VF algorithm, PFS still overestimated CBS. Simple rescaling of surrogate endpoints may not improve their validity within the ASCO-VF given their poor correlations with HR OS–derived CBS.
Development of a Blastoid Variant, Mantle Cell Lymphoma Model in Transgenic Mice.
Authors: Richard J. Ford, Yen-Chiu Lin-Lee, Long Shen, Connie Xu, Chongjie Zhang, Stephen Brooks, John Cowell, Lan V. Pham, Archito T. Tamayo, Linda C. Yoshimura, Julian L. Ambrus
Journal: Blood (2005)
Updated Results of JALSG AML201 Study Comparing Intensified Daunorubicin with Idarubicin in Patients with De Novo Acute Myeloid Leukemia: Effect of Hematopoietic Stem Cell Transplantation.
Authors: Shigeki Ohtake, Shuichi Miyawaki, Hiroyuki Fujita, Hitoshi Kiyoi, Katsuji Shinagawa, Noriko Usui, Kohichi Miyamura, Miki Nishimura, Yasushi Miyazaki, Kazuhiro Nishii, Tadashi Nagai, Takahisa Yamane, Masafumi Taniwaki, Masatomo Takahashi, Fumiharu Yagasaki, Yukihiko Kimura, Norio Asou, Sumihisa Honda, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno
Journal: Blood (2008)
The novel GINS4 axis promotes gastric cancer growth and progression by activating Rac1 and CDC42
Authors: Zhonglin Zhu, Zhilong Yu, Zeyin Rong, Zai Luo, Jing Zhang, Zhengjun Qiu, Chen Huang
Journal: Theranostics (2019)

Rationale: As a component of GINS complex, GINS4 is essential for initiating DNA replication and elongation of the cell cycle G1/S phase in eukaryotes and plays a vital role in normal physiological processes.However, the precise functions and regulation mechanisms of GINS4 in human tumors remain elusive.Methods: GINS4 expression was analyzed in gastric cancer tissues by qRT-PCR and western blotting, and its clinical relevance was studied using TMA.The biological functions of GINS4 were detected in vitro and in vivo.cDNA array, co-IP, GST pull-down and GTPase activation assays were performed to investigate the downstream regulation mechanism of GINS4.Upstream regulation mechanism of GINS4 was explored and demonstrated by circRNA sequencing, bioinformatics analysis, luciferase reporter assay and rescue experiments.Results: Strikingly high GINS4 expression was detected in gastric cancer tissues and correlated with poor differentiation, advanced tumor stage, invasion depth and lymph node metastasis.GINS4 promoted cell growth and metastasis in vitro and in vivo, and suppressed cell apoptosis in vitro.Mechanistically, GINS4 activated Rac1/CDC42 through directly binding to Rac1/CDC42, thereby activating their downstream pathways.Furthermore, circMLLT10 acts as a miR-509-3-5p sponge to attenuate its repressive effect on target GINS4.In addition, circMLLT10 promoted cell growth and metastasis and suppressed cell apoptosis, whereas miR-509-3-5p inhibited cell growth and metastasis and promoted cell apoptosis. Conclusion:The findings indicate for the first time that the novel GINS4 axis promotes gastric cancer cell growth and progression by activating Rac1 and CDC42.GINS4 may be a promising biomarker and target for diagnosis and treatment of gastric cancer.
Giant cell interstitial pneumonia secondary to cobalt exposure from e-cigarette use
Authors: Daffolyn Rachael Fels Elliott, Rupal Shah, Catherine Ann Hess, Brett Elicker, Travis S. Henry, Ana Maria Rule, Rui Chen, Mehdi Golozar, Kirk D. Jones
Journal: European Respiratory Journal (2019)

<b>An e-cigarette user developed giant cell interstitial pneumonia, a rare disease largely limited to work exposure to hard metals, including cobalt. Analysis of the e-liquid identified significant levels of cobalt, supporting the e-cigarette9s causative role.</b>http://bit.ly/2VRcT1U
Abstract 13025: Long-Term Effects of Postconditioning on LV Function and Volumes Following STEMI: A Cardiac MRI Analysis
Authors: Jay H Traverse, Cory Swingen, Timothy D Henry, John Lesser, Jane Fox, Daniel Lips, Yale Wang, Ivan Chavez, Nicholas Burke, Wesley Pedersen, Akila Pai, Jana Lindberg, Ross Garberich
Journal: Circulation (2018)

Introduction: The initial benefit of postconditioning (PC) on infarct size reduction in patients with ST-elevation myocardial infarction (STEMI) has not been consistently demonstrated in the settin...
Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research &amp; discovery of new antibiotics in European countries
Authors: N. Babu Rajendran, N.T. Mutters, G. Marasca, M. Conti, F. Sifakis, C. Vuong, A. Voss, J.R. Baño, E. Tacconelli
Journal: Clinical Microbiology and Infection (2019)

ObjectivesIn 2017 the WHO published a global priority list of 12 antibiotic-resistant bacteria (ARB) in urgent need of new antibiotics. We aimed to identify and assess publicly accessible mandatory surveillance systems and outbreaks reporting for these pathogens in the 28 European Union and four European Free Trade Association member states.MethodsCompulsory reporting was mapped by reviewing national documents without applying language restrictions and through expert consultation. Information on surveillance targets, indicators, metrics and dissemination modalities was extracted and a qualitative assessment was performed for open access systems only.ResultsTwenty-one countries (66%) had a mandate to survey at least one among the 12 WHO priority pathogens; 15 provided access to surveillance frameworks. These systems covered most frequently carbapenem-resistant Enterobacteriales (12; 38%), methicillin-resistant Staphylococcus aureus (12; 38%), and vancomycin-resistant enterococci (8; 25%). None of the European countries required reporting of resistance in Salmonella, Campylobacter, Helicobacter pylori and Neisseria gonorrhoeae. High heterogeneity was observed in data collection, reporting and dissemination among countries with clinical outcomes and risk factors being reported in less than half (22% and 25%). Only six countries (19%) implemented mandatory surveillance of outbreaks due to at least one WHO priority pathogen.ConclusionsOur review shows that despite the increasing burden of ARB on the European population, very few countries implemented mandatory surveillance and outbreak reporting of the WHO priority pathogens. International efforts are needed to define the effectiveness of implementing mandatory reporting of these pathogens and to assess their role in reducing the spread of ARB in health-care and community settings.
综述：强化血糖控制可减少2型糖尿病患者的心血管事件，但没有改变病死率
Authors: 罗丹, 杨彩哲
Journal: BMJ (2010)

综述范围 包括对稳定的2型糖尿病患者采用强化降糖方案与标准方案（安慰剂、标准治疗或低强度的控制）进行对比研究，随访中两组糖化血红蛋白（HbA1c）浓度有明显的组间差异，主要终点为报道的心血管（CV）事件，并对有兴趣的结果提供充分的数据：非致死性心肌梗死，冠状动脉心脏病（CHD），卒中及全因死亡率。其他结果包括HbA1c浓度、心力衰竭、低血糖和体重增加。
ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells
Authors: Tianhui Pan, Jingwen Liu, Song Xu, Qiao Yu, Hongping Wang, Hongxiang Sun, Jia Wu, Yue Zhu, Jianwei Zhou, Yongliang Zhu
Journal: Theranostics (2019)

Background: The leading cause of poor prognosis in colorectal cancer (CRC) is the presence of colorectal cancer-initiating cells (CCICs). The interplay between the tumor microenvironment (TME) and CRC cells induces reacquisition of initiating cell characteristics, but the underlying mechanisms remain elusive. Methods: Candidate molecules were screened by global differential cDNA expression profiles of CCICs, which were enriched from patient-derived tumor xenograft models. Luciferase reporters and chromatin immunoprecipitation assays were used to explore the mechanism of TME factors regulating the transcription of ANKRD22. The effects of Ankyrin repeat domain-containing protein 22 (ANKRD22) on energy metabolism were monitored by extracellular flux and 13C-based metabolic flux analysis. Mass spectrometry was used to identify the interacting partners of ANKRD22. Morphological changes of CCICs overexpressing ANKRD22 were observed by electron microscopy. The effects of ANKRD22 on mitochondrial lipid metabolism were analyzed by lipidomics. Results: We identified a novel nucleus-encoded mitochondrial membrane protein, ANKRD22, which was upregulated in CCICs. We found that ANKRD22 was induced by the p38/MAX pathway activated by different TME stimuli. As a key transcription factor, MAX promoted the transcription of ANKRD22. Expression of ANKRD22 promoted glycolysis associated with a decrease in ATP/ADP and an increase in AMP/ATP levels, which were related to its interaction with pyruvate dehydrogenase kinase isoform 1 (PDK1) and multiple subunits of ATP synthase. Further, in CCICs, ANKRD22 cooperated with the lipid transport protein, Extended Synaptotagmin-1 (E-Syt1), to transport excess lipids into mitochondria and reduced the number of mitochondria in an autophagy-independent manner, thus meeting the metabolic requirements of CCICs. Conclusion: ANKRD22 induced by TME promotes the metabolic reprogramming of CRC cells. Our study has identified ANKRD22/E-Syt1 as a potential target for eradicating CCICs.
Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19–FGFR4–KLB Pathway Inhibition
Authors: Vivek Subbiah, Sumanta K. Pal
Journal: Cancer Discovery (2019)

Abstract Summary: This issue reports two studies, one by Hatlen and colleagues and the other by Kim and colleagues, that detail the drug-development journey of the FGF19–FGFR4 inhibitor fisogatinib (BLU-554), from identification of the drug to preclinical validation studies to finally the results of the proof-of-concept first-in-human phase I trial of this potent and selective, type I irreversible inhibitor of FGFR4. Moreover, Hatlen and colleagues also report a resistance mechanism acquired after therapy that targets selective FGFR4 inhibition, which validates FGF as a specific target in hepatocellular cancer. See related article by Hatlen et al., p. 1686. See related article by Kim et al., p. 1696.
The V617F JAK2 Mutation Is Uncommon in Cancers and Mutations in STAT5A, STAT5B and the JAK Family Genes Do Not Account for V617F Negative Myeloproliferative Disorders.
Authors: Joanna E. Baxter, Linda M. Scott, Peter J. Campbell, Tony Todd, Philip Stephens, Sarah Edkins, Richard Wooster, Michael R. Stratton, Andrew P. Futreal, Anthony R. Green
Journal: Blood (2005)
Erratum. Hostility, race, and glucose metabolism in nondiabetic individuals. Diabetes Care 2002;25:835–839
Authors: Richard S. Surwit, Redford B. Williams, Ilene C. Siegler, James D. Lane, Michael Helms, Katherine L. Applegate, Nancy Zucker, Mark N. Feinglos, Cynthia M. McCaskill, John C. Barefoot
Journal: Diabetes Care (2019)

According to a review conducted by the Duke University Office of Research, Professor Edward C. Suarez was omitted as an author in the above-cited article. The university concluded that Dr. Suarez qualifies …
Hepatotoxicity Profile of Single Agent As 2 O 3 in the Management of Newly Diagnosed Cases of Acute Promyelocytic Leukemia: Impact on Outcome and Correlation with Genetic Polymorphisms.
Authors: Vikram Mathews, Salamun, Biju George, Auro Viswabandya, Kavitha M. Lakshmi, Ashish Bajel, Alok Srivastava, Mammen Chandy
Journal: Blood (2005)
Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent for Prevention of Acute and Chronic Graft Versus Host Disease after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT)
Authors: Leo Luznik, Javier Bolanos-Meade, Robert Brodsky, B. Douglas Smith, Carol A. Huff, Michele Kaup, Allen Chen, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs
Journal: Blood (2008)
肝、胰、胆系统基础知识（二）急性肝炎
Authors: SDRyder, IJBeckingham, 郭慧兰, 周丽雅
Journal: BMJ (2003)

血清丙氨酸氨基转移酶(ALT,即谷-丙转氨酶)活性升高标志着急性肝脏损伤,其活性可以高于正常水平100倍,是目前最好的生化指标。急性肝脏损伤的患者可能也会出现碱性磷酸酶(ALP)和γ-谷氨酰转肽酶(γ-GT)的升高,但升高程度常低于丙氨酸氨基转移酶。
Imatinib Mesylate (IM), Is an Alternative to Donor Lymphocyte Infusion (DLI) for Chronic Myelogenous Leukemia (CML) in Relapse after Allogeneic Stem Cell Transplantation: A 3-Year Follow-Up Report, on the Behalf of the Société Française de Greffe de Moëlle et de Thérapie Cellulaire (SFGM-TC) and the France Intergroupe de la Leucémie Myéloïde Chronique (Fi-LMC).
Authors: Cecile Pautas, Frank Nicolini, Pascal Cony-Makhoul, Stephane Giraudier, Dominique Bories, Agnes Buzyn, Nathalie Dedhin, Mauricette Michallet, François Guilhot, Jean-Pierre Jouet, Mathieu Kuentz
Journal: Blood (2004)
The Oral Off-Patent Antimicrobial Clioquinol Inhibits the Proteasome and Induces Cell Death in AML and Myeloma Cells through a Copper-Dependent Mechanism.
Authors: Xinliang Mao, Xiaoming Li, Rose Hurren, Amudha Venugopal, Suzanne Trudel, A. Keith Stewart, Aaron D. Schimmer
Journal: Blood (2007)
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis
Authors: Adam Zayac, Andrew Matthew Evens, Andrzej Stadnik, Stephen D. Smith, Deepa Jagadeesh, Lori A. Leslie, Catherine Wei, Seo-Hyun Kim, Seema Naik, Suchitra Sundaram, Nishitha Reddy, Umar Farooq, Vaishalee P. Kenkre, Narendranath Epperla, Kristie A. Blum, Nadia Khan, Daulath Singh, Juan Pablo Alderuccio, Amandeep Godara, Maryam Yazdy, Catherine Diefenbach, Emma Rabinovich, Gaurav Varma, Reem Karmali, Yusra Shao, Asaad Trabolsi, Madelyn Burkart, Peter Martin, Sarah Stettner, Ayushi Chauhan, Yun Kyong Choi, Allandria Straker-Edwards, Andreas Klein, Michael C. Churnetski, Kirsten M Boughan, Stephanie Berg, Brad M. Haverkos, Victor M. Orellana-Noia, Christopher D'Angelo, David A. Bond, Seth M Maliske, Ryan Vaca, Gabriela Magarelli, Amy Sperling, Max J. Gordon, Kevin A. David, Paolo Caimi, Manali Kamdar, Craig A. Portell, Parameswaran Venugopal, Izidore S. Lossos, Adam J Olszewski
Journal: Blood (2019)
Final Results of a Phase II Danish Trial Testing Low Dose Total Body Irradiation Following Six Bi-Weekly RCHOP-14 Plus 2 Extra Rituximab in Elderly High risk Patients with Aggressive CD20+ Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Akmal Safwat, Lena Specht, Flemming Hansen, Mads Hansen, Jesper Jurlander, Francesco d’Amore
Journal: Blood (2008)
A Worldwide Meta-Analysis on the Use of Zidovudine and Interferon-alpha for the Treatment of Adult T–Cell Leukemia/Lymphoma.
Authors: Ali Bazarbachi, Gerard Panelatti, Juan Carlos Ramos, Patricia Tortevoye, Zaher Otrock, Graham Taylor, Antoine Gessain, William Harrington, Yves Plumelle, Olivier Hermine
Journal: Blood (2007)
Harnessing tumor-associated macrophages as aids for cancer immunotherapy
Authors: Xiaolei Li, Rui Liu, Xiao Su, Yongsha Pan, Xiaofeng Han, Changshun Shao, Yufang Shi
Journal: Molecular Cancer (2019)

Abstract Cancer immunotherapies that engage immune cells to fight against tumors are proving to be powerful weapons in combating cancer and are becoming increasingly utilized in the clinics. However, for the majority of patients with solid tumors, little or no progress has been seen, presumably due to lack of adequate approaches that can reprogram the local immunosuppressive tumor milieu and thus reinvigorate antitumor immunity. Tumor-associated macrophages (TAMs), which abundantly infiltrate most solid tumors, could contribute to tumor progression by stimulating proliferation, angiogenesis, metastasis, and by providing a barrier against antitumor immunity. Initial TAMs-targeting strategies have shown efficacy across therapeutic modalities and tumor types in both preclinical and clinical studies. TAMs-targeted therapeutic approaches can be roughly divided into those that deplete TAMs and those that modulate TAMs activities. We here reviewed the mechanisms by which macrophages become immunosuppressive and compromise antitumor immunity. TAMs-focused therapeutic strategies are also summarized.
WHO Classification and WPSS Score Predict Post-Transplant Outcome in Adults with Myelodysplastic Syndrome: A Retrospective Study by GITMO - Gruppo Italiano Trapianto Midollo Osseo.
Authors: Paolo E. Alessandrino, Matteo G. Della Porta, Andrea Bacigalupo, Maria Teresa Van Lint, Michele Falda, Francesco Onida, Massimo Bernardi, Anna P. Iori, Alessandro Rambaldi, Raffaella Cerretti, Paola Marenco, Pietro Pioltelli, Cristiana Pascutto, Rosi Oneto, Renato Fanin, Alberto Bosi
Journal: Blood (2007)
New-Onset Heart Failure in a Middle-aged Man
Authors: Stephen E. Wilkinson, Jose Mariano T. Tan, Thomas F. Boyden
Journal: JAMA Cardiology (2019)

A man in his mid-60s presents with dyspnea with moderate levels of physical activity that are occasionally associated with brief episodes of lightheadedness, orthopnea, and tachypnea with a respiratory rate of 24 breaths per minute. What would you do next?
A Nationwide Survey of Immunosuppressive Therapy for Idiopathic Acquired Pure Red Cell Aplasia in Japan and a Proposal for First-Line Treatment: Report of the PRCA Collaborative Study Group.
Authors: Makoto Hirokawa, Ken-ichi Sawada, Mutsuhito Motegi, Shigeo Mamiya, Masanao Teramura, Shinji Nakao, Keiya Ozawa, Akio Urabe, Mitsuhiro Omine
Journal: Blood (2005)
Identification of a Diagnostic Gene Signature for SGN-40, Anti-CD40 Monoclonal Antibody, in Pre-Clinical NHL Models and the Role of FAS in SGN-40 Mediated Apoptosis.
Authors: Xiaoyan Shi, Bart Burington, Tom Januario, Jeffrey T Lau, Shang-Fan Yu, Allen Ebens, David Dornan
Journal: Blood (2008)
Extracellular vesicles of carcinoma-associated fibroblasts creates a pre-metastatic niche in the lung through activating fibroblasts
Authors: Jing Kong, Hongzhu Tian, Fuyin Zhang, Zebing Zhang, Jiao Li, Xue Liu, Xiancheng Li, Jing Liu, Xiaojie Li, Dong Jin, Xuesong Yang, Bo Sun, Tao Guo, Yong Luo, Yao Lu, Bingcheng Lin, Tingjiao Liu
Journal: Molecular Cancer (2019)

Abstract Objectives Carcinoma-associated fibroblasts (CAFs) have been known to promote cancer progression by modifying the primary tumor microenvironment. We aimed to elucidate the intercellular communication between CAFs and secondary organs in salivary adenoid cystic carcinoma (SACC) metastasis. Methods Pre-metastatic and metastatic animal models of SACC were established using extracellular vesicles (EVs) from CAFs and SACC cells. Lung fibroblasts (LFs) were treated with EVs and their transcriptomic alterations were identified by RNA sequencing. ITRAQ were performed to analyze EV cargos. TC I-15 was used to inhibit EV uptake by LFs and SACC lung metastasis in vivo. Results Here, we show that CAF EVs induced lung pre-metastatic niche formation in mice and consequently increased SACC lung metastasis. The pre-metastatic niche induced by CAF EVs was different from that induced by SACC EVs. CAF EVs presented a great ability for matrix remodeling and periostin is a potential biomarker characterizing the CAF EV-induced pre-metastatic niche. We found that lung fibroblast activation promoted by CAF EVs was a critical event at the pre-metastatic niche. Integrin α2β1 mediated CAF EV uptake by lung fibroblasts, and its blockage by TC I-15 prevented lung pre-metastatic niche formation and subsequent metastasis. Plasma EV integrin β1 was considerably upregulated in the mice bearing xenografts with high risk of lung metastasis. Conclusions We demonstrated that CAF EVs participated in the pre-metastatic niche formation in the lung. Plasma EV integrin β1 might be a promising biomarker to predict SACC metastasis at an early stage. An integrated strategy targeting both tumor and stromal cells is necessary to prevent SACC metastasis.
Two-dimensional nanomaterials beyond graphene for antibacterial applications: current progress and future perspectives
Authors: Linqiang Mei, Shuang Zhu, Wenyan Yin, Chunying Chen, Guangjun Nie, Zhanjun Gu, Yuliang Zhao
Journal: Theranostics (2019)

The marked augment of drug-resistance to traditional antibiotics underlines the crying need for novel replaceable antibacterials.Research advances have revealed the considerable sterilization potential of two-dimension graphene-based nanomaterials.Subsequently, two-dimensional nanomaterials beyond graphene (2D NBG) as novel antibacterials have also demonstrated their power for disinfection due to their unique physicochemical properties and good biocompatibility.Therefore, the exploration of antibacterial mechanisms of 2D NBG is vital to manipulate antibacterials for future applications.Herein, we summarize the recent research progress of 2D NBG-based antibacterial agents, starting with a detailed introduction of the relevant antibacterial mechanisms, including direct contact destruction, oxidative stress, photo-induced antibacterial, control drug/metallic ions releasing, and the multi-mode synergistic antibacterial.Then, the effect of the physicochemical properties of 2D NBG on their antibacterial activities is also discussed.Additionally, a summary of the different kinds of 2D NBG is given, such as transition-metal dichalcogenides/oxides, metal-based compounds, nitride-based nanomaterials, black phosphorus, transition metal carbides, and nitrides.Finally, we rationally analyze the current challenges and new perspectives for future study of more effective antibacterial agents.This review not only can help researchers grasp the current status of 2D NBG antibacterials, but also may catalyze breakthroughs in this fast-growing field.